CA-TSG-CONSUMER-PARTNERS
25.3.2019 12:01:06 CET | Business Wire | Press release
TSG Consumer Partners (“TSG”), a leading private equity firm focused exclusively on the branded consumer sector, today announced that it has opened an office in London, its first office outside the U.S.
TSG’s presence in London deepens its commitment to the European market and enhances the firm’s ability to identify and execute on compelling investment opportunities in the region. TSG’s foothold in Europe comes following a series of investments in leading European companies such as Revolution Beauty – which was recently named the third fastest growing private company by the Sunday Times Fast Track 100 – BrewDog, Canyon Bicycles, Bergfreunde.de, as well as ZOEVA and HUDA Beauty, both of which opened offices in London last year.
Beth Pickens, former Managing Director and head of European consumer banking at William Blair, has joined TSG as a Principal based in London. Colin Welch, Partner and Managing Director at TSG, is responsible for guiding the new office located in Mayfair.
“Europe represents a dynamic and attractive marketplace with exciting investment opportunities across the consumer and retail spectrum,” said Chuck Esserman, CEO and Founder of TSG Consumer Partners. “TSG has a strong track record in Europe, and the size of our business has grown steadily over the past few years – one-third of the capital from our TSG7 fund was deployed overseas, primarily on the continent. Now with an established office in London, we will be better positioned to collaborate closely with leading brands and their management teams to help them reach their full global potential.”
Colin Welch commented, “The addition of a London office further positions us as the partner of choice for consumer companies throughout Europe, particularly those looking to capitalize on cross border growth opportunities. It also helps us create additional value for our U.S.-based partner companies as they expand their overseas operations. I am thrilled to work closely with Beth, as we collaborate to identify new investment opportunities and accelerate our momentum in the region.”
Beth Pickens added, “TSG is the pre-eminent investor in the consumer sector and their collaborative approach, and appreciation of the power of an entrepreneur’s vision, makes the firm truly unique. I’m excited to be joining Colin and the talented team at TSG, as we deepen TSG’s European presence and continue to back the global growth of strong consumer brands.”
Beth Pickens joins TSG with nearly two decades of investment banking experience, most recently as Managing Director and head of European consumer banking at William Blair in London. In addition to providing strategic and financial advice to companies across the consumer sector, Ms. Pickens founded William Blair’s European consumer practice, and has been based in London since 2001. Her notable engagements include advising Rapha Racing Limited on its sale to RZC Investments, Happy Socks AB on its sale to Palamon Capital Partners and the initial public offering and follow-on offerings for Tumi.
Ms. Pickens received a Master of Business Administration from the University of Chicago Graduate School of Business, and a Bachelor of Science in Finance from the University of Illinois.
About TSG Consumer Partners
TSG Consumer Partners, LLC is a leading private equity firm focused exclusively on the branded consumer sector. Since its founding in 1987, TSG has been an active investor in the food, beverage, restaurant, beauty, personal care, fitness, health & wellness, household, apparel & accessories, and e-commerce sectors. Representative past and present partner companies include Duckhorn Wine Company, Planet Fitness, IT Cosmetics, REVOLVE, HUDA Beauty, BrewDog, Canyon Bicycles, Pabst, Backcountry, vitaminwater, thinkThin, popchips, Stumptown, Smashbox Cosmetics and e.l.f. Cosmetics. For more information, visit tsgconsumer.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005254/en/
Contact:
TSG Consumer Partners Sard Verbinnen & Co Conrad Harrington / Dan Goldstein / Julie Rudnick +44 20 7467 1050 / 310-201-2040 / 212-687-8080
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
